Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

Fake botox seized in Cincinnati
Americas
US authorities have seized thousands of dollars worth of counterfeit Botox injections in shipments in a Cincinnati port, the US Customs and Border Protection (CBP) office announced yesterday, July 30.   31 July 2020
AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment
Pharma
Biopharmaceutical company AstraZeneca has struck a deal with Japanese pharmaceutical company Daiichi Sankyo to jointly develop and market a new medicine to treat lung, breast and other cancers.   30 July 2020
US authorities seize counterfeit Viagra and Zantac at airport
Americas
Counterfeit pills used to treat erectile dysfunction, heartburn and stomach ulcers have been discovered at Los Angeles International Airport (LAX), alongside fake luxury goods.   30 July 2020
Biotech
The University of Texas is protected from being forced to become an involuntary plaintiff in an infringement suit because of sovereign immunity, the US Court of Appeals for the Federal Circuit ruled on Friday, July 24.   28 July 2020
Pharma
Biotech company Moderna has failed to have a US patent owned by its competitor Arbutus Biopharma revoked, following a decision handed down by the Patent Trial and Appeal Board (PTAB).   24 July 2020
Pharma
The US International Trade Commission (USITC) will investigate Regeneron Pharmaceuticals for the alleged infringement of a patent owned by its rival Novartis, it announced in a notice posted yesterday, July 21.   22 July 2020
Americas
Two citizens of Ukraine have admitted to smuggling and distributing counterfeit cancer and hepatitis drugs into the US at the Southern District Court of Texas on July 17, according to the US Department of Justice.   20 July 2020
Biotech
Biotechnology company Qiagen has failed in its bid to stop diagnostics company HandyLab from retaining a patent for a diagnostic system, according to a decision issued by the US Patent Trial and Appeal Board on Tuesday, July 14.   20 July 2020
Biotech
The US International Trade Commission (USITC) will take another look at whether German orthopedics company Zimmer Biomet violated the IP rights of medical technology company Heraeus, it announced yesterday, Monday 13 July.   14 July 2020
Biotech
The COVID-19 pandemic poses unprecedented challenges to the biomedical community as it strives to find the best solutions to fight COVID-19.   10 July 2020

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.